MT2020-34: A Phase 3, Open-label, Single Arm, Multicenter Study of Ravulizumab in Addition to Best Supportive Care in Pediatric Participants (from 1 month to < 18 years of age) with Thrombotic Microangiopathy (TMA) after Hematopoietic Stem Cell Transplantation (HSCT)
To assess the efficacy of ravulizumab plus BSC in the treatment of pediatric participants with HSCT-TMA.
Hematopoietic Stem Cell Transplant, Ravulizumab, Thrombotic Microangiopathy (TMA), Ultomiris
Kim Nelson - firstname.lastname@example.org
NCT04557735See this study on ClinicalTrials.gov